QNZ
QNZ (EVP4593) shows strong inhibitory effects on NF-κB transcriptional activation and TNF-α production with IC50s of 11 and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of SOC channel.
Product Specifications
CAS Number
545380-34-5
Product Name Alternative
EVP4593
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
NF-κB; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/QNZ.html
Purity
99.50
Solubility
DMSO : ≥ 37 mg/mL
Smiles
NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1
Molecular Formula
C22H20N4O
Molecular Weight
356.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Tobe M, et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation.|[2]Nekrasov ED, et al. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener. 2016 Apr 14;11:27.|[3]Wu J, et al. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. J Neurosci. 2016 Jan 6;36 (1) :125-41.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NF-κB; TNFRSF5/CD40
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog